Joint effects: A pilot investigation of the impact of bipolar disorder and marijuana use on cognitive function and mood

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Sagar, Kelly A ^a,b   Dahlgren, M Kathryn ^a,c   Racine, Megan T ^a   Dreman, Meredith W ^a   Olson, David P ^a,b   Gruber, Staci A ^a,b  

^a MCLEAN HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BENZODIAZEPINE DERIVATIVE; CANNABIS; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BIPOLAR DISORDER; CANNABIS ADDICTION; CANNABIS SMOKING; CANNABIS USE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMOGRAPHY; DSM-IV; ECOLOGICAL MOMENTARY ASSESSMENT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; NEUROPSYCHOLOGICAL TEST; PILOT STUDY; ADOLESCENT; AFFECT; CLINICAL TRIAL; COGNITION; PATHOPHYSIOLOGY; PSYCHOLOGY;

ADOLESCENT; ADULT; AFFECT; BIPOLAR DISORDER; COGNITION; FEMALE; HUMANS; MALE; MARIJUANA ABUSE; PILOT PROJECTS;

EID: 84975322536     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157060     Document Type: Article

References (74)

1. Woods SW. The economic burden of bipolar disease. Journal of Clinical Psychiatry. 2000; 61: 38-41. PMID: 11153811
2. Strakowski SM, Sax KW, McElroy SL, Keck PE Jr., Hawkins JM, West SA. Course of psychiatric and substance abuse syndromes co-occurring with bipolar disorder after a first psychiatric hospitalization. Journal of Clinical Psychiatry. 1998 Sep; 59(9): 465-471. PMID: 9771817
3. Tohen M, Greenfield SF, Weiss RD, Zarate CA, Vagge LM. The effect of comorbid substance use disorders on the course of bipolar disorder: A review. Harvard Review of Psychiatry. 1998; 6(3): 133-141. PMID: 10372281
4. van Rossum I, Boomsma M, Tenback MD, Reed C, van Os J. Does cannabis use affect treatment outcome in bipolar disorder? A longitudinal analysis. The Journal of Nervous and Mental Disease. 2009 Jan 1; 197(1): 35-40. Available: PMID: 19155808
5. Bolton JM, Robinson J, Sareen J. Self-medication of mood disorders with alcohol and drugs in the National Epidemiologic Survey on Alcohol and Related Conditions. Journal of Affective Disorders. 2009 Jun 30; 115(3): 367-375. Available: doi: 10.1016/j.jad.2008.10.003 PMID: 19004504
6. Bizzarri JV, Sbrana A, Rucci P, Ravani L, Masei GJ, Gonnelli C, et al. The spectrum of substance abuse in bipolar disorder: reasons for use, sensation seeking and substance sensitivity. Bipolar Disorders. 2007 May 1; 9(3): 213-220. PMID: 17430295
7. Strakoswki SM, DelBello MP, Fleck DE, Adler CM, Anthenelli RM, Keck PE et al. Effects of co-occurring cannabis use disorders on the course of bipolar disorder after a first hospitalization for mania. Archives of General Psychiatry. 2007 Jan 1; 64(1): 57-64. PMID: 17199055
8. Agrawal A, Nurnberger JI, Lynskey MT, Study TB. Cannabis involvement in individuals with bipolar disorder. Psychiatry Research. 2011 Feb 28; 185(3): 459-461. Available: doi: 10.1016/j.psychres.2010.07.007 PMID: 20674039
9. Cerullo MA, Strawkoski SM. The prevalence and significance of substance use disorders in bipolar type I and II disorder. Substance Abuse Treatment, Prevention, and Policy. 2007 Oct 1; 2(1): 29.
10. Goldberg JF, Garno JL, Leon AC, Kocsis JH, Portera L. A history of substance abuse complicates remission from acute mania in bipolar disorder. Journal of Clinical Psychiatry. 1999 Nov; 60(11): 733-740. PMID: 10584760
11. Henquet C, Krabbendam L, de Graaf R, ten Have M, van Os J. Cannabis use and expression of mania in the general population. Journal of Affective Disorders. 2006 Oct 31; 95(1): 103-110.
12. Kvitland LR, Melle I, Aminoff SR, Lagerberg TV, Andreassen OA, Ringen PA. Cannabis use in first-treatment bipolar I disorder: relations to clinical characteristics. Early Intervention in Psychiatry. 2014May 1. Available: doi: 10.1111/eip.12138
13. Baethge C, Hennen J, Khalsa HK, Salvator P, Tohen M, Baldessarini RJ. Sequencing of substance use and affective morbidity in 166 first-episode bipolar I disorder patients. Bipolar Disorders. 2008 Sep 1; 10: 738-741. Available: doi: 10.1111/j.1399-5618.2007.00575.x PMID: 18837869
14. Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP. Cannabis use and mania symptoms: A systematic review and meta-analysis. Journal of Affective Disorders. 2015 Jan17; 171: 39-47. Available: doi: 10.1016/j.jad.2014.09.016 PMID: 25285897
15. Tijssen MJ, Van Os J, Wittchen HU, Lieb R, Bessdo K, Wichers M. Risk factors predicting onset and persistence of subthreshold expression of bipolar psychopathology among youth from the community. Psychiatrica Scandinavica. 2010 Sep 1; 122(3): 255-266. Available: doi: 10.1111/j.1600-0447.2010.01539.x
16. van Laar M, van Dorsselaer S, Monshouwer K, de Graaf R. Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population? Addiction. 2007 Aug 1; 102(8): 1251-1260. PMID: 17624975
17. Grinspoon L, Bakalar JB. The use of cannabis as a mood stabilizer in Bipolar Disorder: Anecdotal evidence and the need for clinical research. Journal of Psychoactive Drugs. 1998 Jun 1; 30(2): 171-177. PMID: 9692379
18. Gruber AJ, Pope HG, Brown ME. Do patients use marijuana as an antidepressant? Depression. 1996 Jan 1; 4(2): 77-80. PMID: 9160645
19. Healey C, Peters S, Kinderman P, McCracken C, Morriss R. Reasons for substance use in dual diagnosis bipolar disorder and substance use disorders: A qualitative study. Journal of Affective Disorders. 2009 Feb 28; 113(1): 118-126. Available: doi: 10.1016/j.jad.2008.05.010
20. Merikangas KR, Herrell R, Swendsen J, Rossler W, Ajdacic-Gross V, Angst J. Specificity of bipolar spectrum conditions in the comorbidity of mood and substance use disorders. Archives of Genera Psychiatry. 2008 Jan 1; 65(1): 47-52. Available: doi: 10.1001/archgenpsychiatry.2007.18
21. Weiss RD, Kolodziej M, Griffin ML, Najavits LM, Jacobson LM, Greenfield SF. Substance use and perceived symptom improvement among patients with bipolar disorder and substance dependence. Journal of Affective Disorders. 2004 Apr 30; 79(1): 279-283.
22. Ashton CH, Moore PB, Gallagher P, Young AH. Cannabinoids in bipolar affective disorder: A review and discussion of their therapeutic potential. Journal of Psychopharmacology. 2005 May 1; 19(3): 293-300. PMID: 15888515
23. Hurd YL, Michaelides M, Miller ML, Jutras-Aswad D. Trajectory of adolescent cannabis use on addiction vulnerability. Neuropharmacology. 2014 Jan 31; 76: 416-424. Available: doi: 10.1016/j.neuropharm.2013.07.028 PMID: 23954491
24. Shiffman S, Stone AA, Hufford MR. Ecological momentary assessment. Annual Review of Clinical Psychology. 2008 Apr 27; 4(1): 1-32.
25. Trull TJ, Ebner-Priemer UW. Using experience sampling Methods/Ecological momentary assessment (ESM/EMA) in clinical assessment and clinical research: Introduction to the special section. Psychological Assessment. 2009; 21(4): 457-462. Available: doi: 10.1037/a0017653 PMID: 19947780
26. Sato H, Kawahara J. Selective bias in retrospective self-reports of negative mood states. Anxiety, Stress & Coping. 2011 Jul 1; 24(4): 359-367. Available: doi: 10.1080/10615806.2010.543132
27. Myin-Germeys I, Oorschot M, Collip D, Lataster J, Delespaul P, van Os J. Experience sampling research in psychopathology: opening the black box of daily life. Psychological Medicine. 2009 Sep 1; 39(9): 1533-1547. Available: doi: 10.1017/S0033291708004947 PMID: 19215626
28. Ehrenreich H, Rinn T, Kunert HJ, Moeller MR, Poser W, Schilling L. Specific attentional dysfunction in adults following early start of cannabis use. Psychopharmacology. 1999 Mar 1; 142(3): 295-301. PMID: 10208322
29. Nestor L, Roberts G, Garavan H, Nestor R. Deficits in learning and memory: parahippocampal hyperactivity and frontocortical hypoactivity in cannabis users. Neuroimage. 2008 Apr 15; 40(3): 1328-1339. Available: doi: 10.1016/j.neuroimage.2007.12.059 PMID: 18296071
30. Wagner D, Becker B, Gouzoulis-Mayfrank G, Daumann J. Interactions between specific parameters of cannabis use and verbal memory. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2010 Aug 16; 34(6): 871-876. Available: doi: 10.1016/j.pnpbp.2010.04.004
31. Yücel M, Solowij N, Respondek C, Whittle S, Fornito A, Pantelis C, et al. Regional brain abnormalities associated with long-term heavy cannabis use. Archives of General Psychiatry. 2008 Jun 2; 65(6): 694-701. Available: doi: 10.1001/archpsyc.65.6.694 PMID: 18519827
32. Filbey FM, Aslan S, Calhoun VD, Spence JS, Damaraju E, Capriahn A, et al. Long-term effects of marijuana use on the brain. Proceedings of the National Academy of Sciences of the United States of America. 2014 Nov 25; 111(47):16913-8. pii: 201415297. doi: 10.1073/pnas.1415297111 PMID: 25385625
33. Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. Proceedings from the National Academic of Sciences of the United States of America. 2012 Oct 2; 109(4): E2657-E2664.
34. Pope HG, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: What is the nature of the association? Drug and Alcohol Dependence. 2003 Apr 1; 69(3): 303-310. PMID: 12633916
35. Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, et al. Cannabis use before age 15 and subsequent executive functioning. British Journal of Psychiatry. 2011 Jun 1; 198(6): 442-447. Available: doi: 10.1192/bjp.bp.110.077479 PMID: 21628706
36. Gruber SA, Dahlgren MK, Saga KA, Gönenç A, Killgore WD. Age of onset of marijuana use impacts inhibitory processing. Neuroscience Letters. 2012a Mar 9; 511(2): 89-94. Available: doi: 10.1016/j.neulet.2012.01.039
37. Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PC, et al. Reflection impulsivity in adolescent cannabis users: a comparison with alcohol-using and non-substance-using adolescents. Psychopharmacology. 2012 Jan 1; 219(2): 575-586. Available: doi: 10.1007/s00213-011-2486-y PMID: 21938415
38. Bourne C, Aydemir O, Balanza-Martinez V, Bora E, Brissos S, Cavanagh JT, et al. Neuropsychological testing of cognitive impairment in euthymic bipolar disorder: An individual patient data meta-analysis. Acta Psychiatrica Scandinavica. 2013 Sep 1; 129(3): 149-162. Available: doi: 10.1111/acps.12133
39. Robinson LJ, Thompson JM, Gallagher P, Goswami U, Young AH, Ferrier IN, et al. A meta-analysis of cognitive deficits in euthymic patients with bipolar disorder. Journal of Affective Disorders. 2006 Jul 31; 93(1): 105-115.
40. Ringen PA, Vaskinn A, Sundet K, Engh JA, Jónsdóttir H, Simonsen C, et al. Opposite relationships between cannabis use and neurocognitive functioning in bipolar disorder and schizophrenia. Psychological Medicine. 2010 Aug 1; 40(8): 1337-1347. Available: doi: 10.1017/S0033291709991620 PMID: 19891810
41. Braga RJ, Burdick KE, DeRosse P, Malhotra AK. Cognitive and clinical outcomes associated with cannabis use in patients with bipolar I disorder. Psychiatry Research. 2012 Dec 30; 200(2-3): 242-245. Available: doi: 10.1016/j.psychres.2012.05.025 PMID: 22818174
42. First MB, Spitzer RL, Gibbon M, Williams BW. Structured clinical interview for axis I DSM IV disorder, patient edition (SCID-I/P). Version 2.0. New York, NY: Biometric Research Department, NY State Psychiatric Institute. 1994.
43. Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE. Age of onset of marijuana use and executive function. Psychology of Addictive Behaviors. 2012a Sep; 26(3): 496-506. Available: doi: 10.1037/a0026269
44. Gruber SA, Dahlgren MK, Sagar KA, Gönenç A, Lukas SE. Worth the wait: Effects of age of onset of marijuana use on white matter and impulsivity. Psychopharmacology. 2014 Apr 1; 231(8):1455-1465. Available: doi: 10.1007/s00213-013-3326-z PMID: 24190588
45. Pollock V, Cho DW, Reker D, Volavka J. Profile of Mood States: the Factors and Their Physiological Correlates. The Journal of Nervous and Mental Disease. 1979 Oct 1; 167(10): 612-614. PMID: 226658
46. Hamilton MA. The assessment of anxiety states by rating. British Journal of Medical Psychology. 1959 Mar 1; 32(1): 50-55. PMID: 13638508
47. Montgomery SA, Asberg MA. A new depression scale designed to be sensitive to change. The British Journal of Psychiatry. 1979 Apr 1; 134(4): 561-571.
48. Young RC, Biggs JT, Ziegler VE, Meyer DA. A rating scale for mania: reliability, validity and sensitivity. The British Journal of Psychiatry. 1978 Nov 1; 133(5): 429-435.
49. Wechsler D. Wechsler Abbreviated Scale of Intelligence. San Antonio, TX: The Psychological Corporation. 1999.
50. Berg EA. A simple objective technique for measuring flexibility in thinking. The Journal of General Psychology. 1948 Jul 1; 39(1): 15-22.
51. Lezak MD, Howieson DB, Loring DW. Neuropsychological assessment. New York: Oxford University Press. 2004.
52. MacLeod CM. Half a century of research on the Stroop effect: An integrative review. Psychological Bulletin. 1991 Mar; 109(2): 163-203. PMID: 2034749
53. Bryan J, Luszcz MA. Measurement of executive function: Considerations for detecting adult age differences. Journal of Clinical and Experimental Neuropsychology. 2000 Feb 1; 22(1): 40-55. PMID: 10649544
54. Denckla MB. Measurement of Executive Function. In Reid L. (Ed.), Frames of reference for the assessment of learning disabilities: New views on measurement issues. Baltimore, MD: Paul H Brookes Publishing; 1994. p.117-142.
55. Wechsler D. Manual for the Wechsler Adult Intelligence Scale. New York, NY: The Psychological Corporation. 1955.
56. Wechsler D. Manual for the Wechsler Adult Intelligence Scale - Revised. New York, NY: The Psychological Corporation. 1981.
57. Delis DC, Karmer JH, Kaplan E, Ober BA. California verbal learning test: Adult version. San Antonio, TX: The Psychological Corporation. 1987.
58. Hooper HE. The Hooper Visual Organization Test manual. Los Angeles, CA: Western Psychological Services. 1958.
59. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: A revision of the Fagerstrom Tolerance Questionnaire. British Journal of Addictions. 1991 Sep 1; 86(9): 1119-1127.
60. McLellan AT, Luborsky L, O'Brien CP, Woody GE. An improved diagnostic instrument for substance abuse patients: The Addiction Severity Index. Journal of Nervous & Mental Diseases. 1980 Jan 1; 168 (1): 26-33.
61. Sobell LC, Sobell MB, Leo GI, Cancilla A. Reliability of a timeline method: Assessing normal drinkers' reports of recent drinking and a comparative evaluation across several populations. British Journal of Addiction. 1998 Apr 1; 83(4): 393-402.
62. Crane NA, Schuster RM, Fusar-Poli P, Gonzalez R. Effects of cannabis on neurocognitive functioning: Recent advances, neurodevelopmental influences, and sex differences. Neuropsychology Review. 2013 Jun 1; 23(2): 117-137. Available: doi: 10.1007/s11065-012-9222-1 PMID: 23129391
63. Crean RD, Crane NA, Masson BJ. Evidence based review of acute and long-term effects of cannabis use on executive cognitive functions. Journal of Addiction Medicine. 2011 Mar 1; 5(1): 1-8. Available: PMID: 21321675
64. Lisdahl KM, Wright NE, Kirchner-Medina C, Maple KE, Shollengarger S. Considering cannabis: The effects of regular cannabis use on neurocognition in adolescents and young adults. Current Addiction Reports. 2014 Jun 1; 1(2): 144-156. PMID: 25013751
65. Cahill CM, Cohen M, Ivanovski B, Lagopoulous J, Malhi GS. Cognitive compromise in bipolar disorder with chronic cannabis use: Cause of consequence? Expert Review of Neurotherapeutics. 2006; 6: 591. PMID: 16623657
66. Tyler E, Jones S, Black N, Carter LA, Barrowclough C. The relationship between bipolar disorder and cannabis use in daily life: An experience sampling study. PLoS On. 2015 Mar 1; 10(3): e0123953. Available: doi: 10.1371/journal.pone.0118916
67. Mechoulam R, Parker LA, Gallily R. Cannabidiol: An overview of some pharmacological aspects. Journal of Clinical Pharmacology. 2002 Nov 1; 42(S1): 11S-19S.
68. Schier AR, Ribeiro NP, Silva AC, Hallak JE, Crippa JA, Nardi AE, et al. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Revista Brasileira de Psiquiatria. 2012 Jun; 34: S104-110. PMID: 22729452
69. Zuardi AW, Crippa JA, Hallak JE, Bhattacharyya S, Atakan Z, Martin-Santos R, et al. A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Current Pharmaceutical Design. 2012 Jun 7; 18(32): 5131-5140. PMID: 22716160
70. Rosenberg EC, Tsien RW, Whalley BJ, Devinsky O. Cannabinoids and epilepsy. Neurotherapeutics. 2015 Oct 1; 12(4): 747-768. doi: 10.1007/s13311-015-0375-5 PMID: 26282273
71. Power BD, Dragovic M, Badcock JC, Morgan VA, Castle D, Jablensky A, et al. No additive effect of cannabis on cognition in schizophrenia. Schizophrenia Research. 2015 Oct 31; 168(1): 245-251. Available: doi: 10.1016/j.schres.2015.06.026
72. Simon NM, Otto MW, Wisniewski SR, Fossey M, Sagduyu K, Frank E, et al. Anxiety disorder comorbidity in bipolar disorder patients: Data from the first 500 participants in the systematic treatment enhancement program for bipolar disorder (STEP-BD). The American Journal of Psychiatry. 2004 Dec 1; 161: 2222-2229. PMID: 15569893
73. Substance Abuse and Mental Health Services Administration. Results from the 2012 National Survey on Drug Use and Health: Summary of National Findings, NSDUH Series H-46, HHS Publication No. (SMA) 13-4795. Rockville, MD: Substance Abuse and Mental Health Services Administration. 2013.
74. Johnston LD, O'Malley PM, Miech RA, Bachman JG, Schulenberg JE. Monitoring the Future national results on drug use: 1975-2014. Ann Arbor: Institute for Social Research, The University of Michigan. 2014.